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Abstract
 
The predisposition of nonobese diabetic (NOD) mice to develop autoimmunity reflects defi-
ciencies in both peripheral and central tolerance. Several defects have been described in these
mice, among which aberrant antigen-presenting cell function and peroxynitrite formation.
Prediabetes and diabetes in NOD mice have been targeted with different outcomes by a variety
of immunotherapies, including interferon (IFN)-
 
 
 
. This cytokine may be instrumental in
specific forms of tolerance by virtue of its ability to activate immunosuppressive tryptophan
catabolism. Here, we provide evidence that IFN-
 
 
 
 fails to induce tolerizing properties in den-
dritic cells from highly susceptible female mice early in prediabetes. This effect is associated
with impaired tryptophan catabolism, is related to transient blockade of the Stat1 pathway of
intracellular signaling by IFN-
 
 
 
, and is caused by peroxynitrite production. However, the use
of a peroxynitrite inhibitor can rescue tryptophan catabolism and tolerance in those mice. This
is the first report of an experimental autoimmune disease in which defective tolerance is caus-
ally linked to impaired tryptophan catabolism.
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Introduction
 
The nonobese diabetic (NOD)
 
*
 
 strain of mice has become
a prototypic model of autoimmune disease (1, 2). A large
proportion of female mice generally die of type 1 diabetes,
reflecting the onset of severe insulitis at 
 
 
 
4 wk of age and
the T cell–mediated destruction of pancreatic 
 
 
 
 cells. The
predisposition of NOD mice to develop autoimmunity is
presumably due to defects in both peripheral and central
tolerance mechanisms (3). Several abnormalities have been
described in these mice, including aberrant APC function
(4), IL-12 production (5), and peroxynitrite formation (6).
Among the immunotherapies that may oppose the onset
or progression of autoimmune diabetes is the use of proin-
flammatory cytokines, such as TNF-
 
 
 
 and IFN-
 
 
 
. There
are, however, remarkable differences in the modulation of
susceptibility to diabetes by immunotherapeutic maneu-
vers, depending on timing of intervention. For example,
TNF-
 
 
 
 increases T cell autoreactivity to islet cells and ex-
acerbates diabetes when administered from birth to 3 wk of
age. In contrast, the administration of TNF-
 
 
 
 to adult
NOD mice will block progression of the autoreactive
process (7). IFN-
 
 
 
 is protective when used in the form of
recombinant cytokine administered in vivo to diabetic
mice (8) or as a means of conditioning DCs in vitro before
transfer into prediabetic recipients (9).
Although the protective effect of IFN-
 
 
 
 in NOD mice
may appear paradoxical (8), we have proposed a model of
transplantation tolerance that might help to explain the
therapeutic efficacy of the recombinant cytokine in both
transplantation and autoimmunity (10). According to this
model, IFN-
 
 
 
 acts on tolerogenic DCs to activate the
expression of the enzyme indoleamine 2,3-dioxygenase
(IDO). This leads to the induction of immunosuppressive
tryptophan catabolism and to the onset of specific tolerance
(11, 12).
In the present study, we have investigated the possible
interplay between the onset of specific tolerance and tryp-
tophan catabolism in NOD mice. We provide evidence
that IFN-
 
 
 
 is selectively unable to induce tolerizing prop-
erties in DCs from female mice early in prediabetes. This
effect can be traced to peroxynitrite-induced blockade of
IFN-
 
 
 
 signaling through Stat1, and results in impaired
transcriptional activation of the IDO gene. Thus, in this
model of autoimmune disease, an age-related defect is
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found in susceptible mice that affects DC function, tryp-
tophan catabolism, and the induction of specific tolerance.
 
Materials and Methods
 
Mice and Reagents.
 
Female and male NOD/LtJ mice, 4 and
8 wk of age, were purchased from The Jackson Laboratory. The
mice were housed and fed under specific pathogen-free condi-
tions. Autoimmune diabetes develops in 
 
 
 
80% of NOD/LtJ fe-
male mice by 1 yr of age. Female DBA/2J and C57BL/6 mice
were also purchased from The Jackson Laboratory. The source
and characteristics of the murine rIL-12 and murine rIFN-
 
 
 
 were
described previously (13). Endotoxin was removed from all solu-
tions containing recombinant cytokines with Detoxy-gel (Pierce
Chemical Co.), resulting in endotoxin contamination below the
detection limit (0.01 endotoxin U/ml) of the assay (Coatest En-
dotoxin; Chromogenix). NRP-A7 (KYNKANAFL), a synthetic
peptide that acts as a mimotope for autoimmune diabetes in
NOD mice (14, 15), was synthesized and purified as described
(13). The enzyme inhibitors 1-methyl-
 
dl
 
-tryptophan (1-MT)
and guanidinoethyl disulphide (GED) were purchased from
Sigma-Aldrich. All in vivo studies were done in compliance with
National and Perugia University Animal Care and Use Commit-
tee guidelines.
 
DC Preparations and Treatments and Immunization.
 
Splenic
DCs were prepared from pools of at least five mice and fraction-
ated according to CD11c/CD8
 
 
 
 expression using positive selec-
tion columns in combination with CD11c and CD8
 
 
 
 micro-
beads
 
®
 
 and in the presence of EDTA to disrupt DC-T cell
complexes, as described previously (13). The recovered cells were
 
 
 
98% CD11c
 
 
 
, 
 
 
 
98% B7–2
 
 
 
, 
 
 
 
0.1% CD3
 
 
 
, 
 
 
 
0.5% B220
 
 
 
. In
NOD mice of either sex, DCs consisted of 80–85% CD8
 
 
 
 and
15–20% CD8
 
 
 
 cells. After cell fractionation, the recovered CD8
 
 
 
cells typically contained 
 
 
 
0.5% contaminating CD8
 
 
 
 DCs,
whereas the CD8
 
 
 
 fraction was made up of 
 
 
 
95% CD8
 
 
 
 DCs.
For cytokine activation, DCs were subjected to overnight expo-
sure to 100 ng/ml rIL-12 (CD8
 
 
 
 DCs) or 200 U/ml IFN-
 
 
 
(CD8
 
 
 
 DCs) in the presence or absence of 2 
 
 
 
M 1-MT or 250
 
 
 
M GED. For immunization, cells were washed between and af-
ter incubations before peptide loading (5 
 
 
 
M, 2 h at 37
 
 
 
C), irra-
diation, and intravenous injection into recipient hosts. Three 
 
 
 
10
 
5
 
 CD8
 
 
 
 DCs were injected either alone or in combination
with 9 
 
 
 
 10
 
3
 
 CD8
 
 
 
 DCs.
 
Skin Test Assay.
 
A skin test assay was used for measuring class
I–restricted delayed-type hypersensitivity responses to synthetic
peptides as previously described (16, 17), using 4-wk-old NOD
female mice as recipients. Results were expressed as the increase
in footpad weight of peptide-injected footpads over that of vehi-
cle-injected counterparts. Data are the mean 
 
 
 
 SD for at least six
mice per group. The statistical analysis was performed using Stu-
dent’s paired 
 
t
 
 test by comparing the mean weight of experimen-
tal footpads with that of control counterparts.
 
Kynurenine Assay.
 
IDO functional activity was measured in
vitro in terms of ability of DCs to metabolize tryptophan to
kynurenine, whose concentrations were measured by HPLC as
described (18).
 
Western Blot Analyses.
 
IDO expression was investigated as
described (10, 18) using a specific Ab in CD8
 
 
 
 DCs, either un-
treated or exposed to IFN-
 
 
 
 in the presence or absence of GED.
After incubation with medium or IFN-
 
 
 
 (200 U/ml for 18 h),
cells were recovered and lysed in buffer containing 1% Nonidet
P-40. After SDS-PAGE resolution, immunoblotting was per-
formed with rabbit polyclonal IDO-specific antibody. Mem-
branes were blocked in Tris-buffered saline containing 0.05%
Tween 20, 5% nonfat dried milk, and 1% BSA, and incubated se-
quentially with the antibody (1:3,000) and HRP-conjugated
anti–rabbit IgG (1:5,000). Controls consisted of IDO-expressing
MC
 
24
 
 transfectants and mock-transfected MC
 
22
 
 cells. On study-
ing Stat1 phosphorylation, CD8
 
 
 
 DCs were exposed overnight
to 250 
 
 
 
M GED and then treated with IFN-
 
 
 
 (200 U/ml) for 10
min. After SDS-PAGE resolution, immunoblotting was per-
formed with anti-Stat1 Abs. Membranes were blocked in Tris-
buffered saline containing 0.05% Tween 20, 5% nonfat dried
milk, and 1% BSA, and incubated sequentially with anti-
phosphoStat1 (1:1,000; Cell Signaling Technology) and anti-
Stat1 (1:1,000; Cell Signaling Technology), followed by HRP-
conjugated anti-rabbit IgG (1:5,000).
 
Nitrotyrosine ELISA.
 
The assay was performed using a Nitro-
tyrosine ELISA kit (HyCult biotechnology b. v.) according to
manufacturer’s instructions. Briefly, ELISA plates coated with ni-
trotyrosine Ab were incubated with nitrated proteins as antigen
(100 
 
 
 
l/well) for 1 h. The plates were then incubated with bio-
tinylated Ab to nitrotyrosine in protein-stabilized buffer. Subse-
quently, plates were incubated with streptavidin peroxydase con-
jugate followed by specific substrate. The kit has a minimum
detection level of 2 nM and a measurable concentration range of
2 to 1,500 nM.
 
Results
 
Failure of IFN-
 
 
 
 and CD8
 
 
 
 DCs from NOD Female Mice
to Initiate IDO-dependent Tolerance in Prediabetes.
 
NRP-A7
is a synthetic nonapeptide that elicits the proliferation, cy-
tokine secretion, differentiation, and cytotoxicity of a dia-
betogenic H-2K
 
d
 
–restricted CD8
 
 
 
 T cell specificity that
uses a TCR
 
 
 
 rearrangement frequently expressed by
CD8
 
 
 
 T cells propagated from the earliest insulitic lesions
of NOD mice (14, 15). Cell populations in the spleens of
conventional strains of mice contain variable proportions
of mature CD8
 
 
 
 and CD8
 
 
 
 DCs that mediate the respec-
tive immunogenic and tolerogenic presentation of NRP-
A7. Upon transfer into recipient hosts, peptide-loaded
CD8
 
 
 
 DCs initiate immunity, and CD8
 
 
 
 DCs initiate an-
ergy, when antigen-specific skin test reactivity is measured
at 2 wk after cell transfer. The addition of as few as 3%
CD8
 
 
 
 DCs to a population of CD8
 
 
 
 DCs inhibits prim-
ing by the latter cells in this model of class I–restricted re-
activity to the synthetic peptide (13, 17). We examined
CD8
 
 
 
 and CD8
 
 
 
 DCs from NOD mice for their patterns
of presentation of NRP-A7 in vivo. Female mice of two
different ages, 4 and 8 wk, were used as a source of splenic
DCs that were fractionated, loaded with the peptide, and
injected into recipient hosts to be assayed at 2 wk for
NRP-A7-specific skin test reactivity. CD8
 
 
 
 DCs were in-
jected either alone or in combination with 3% CD8
 
 
 
DCs, and each subset was used either as such or after ex-
posure to IL-12 (for CD8
 
 
 
 DCs) or IFN-
 
 
 
 (for CD8
 
 
 
DCs; Fig. 1). Presentation by CD8
 
 
 
 DCs resulted in effec-
tive priming, which effect was negated by the copresence
of CD8
 
 
 
 DCs in the cell transfer. Similar to what ob-
served in conventional mice (16), the suppressive effect of
IFN-
 
 
 
 prevailed over the adjuvant activity of IL-12 acting
on CD8
 
 
 
 DCs when 8-wk-old mice were used as a sourceT
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of DCs. The effect of IFN-
 
 
 
 was dependent upon effec-
tive tryptophan catabolism, as it was ablated by the addi-
tion of the IDO enzyme inhibitor, 1-MT, during CD8
 
 
 
DC exposure to the cytokine. In contrast, IFN-
 
 
 
 was
completely unable to induce suppressive properties in
CD8
 
 
 
 DCs from 4-wk-old mice and thus overcome the
stimulatory activity of IL-12. In experiments not reported
here using male mice, we found that IFN-
 
 
 
 acted equally
well in CD8
 
 
 
 DCs from donors of 4 or 8 wk of age. Thus,
CD8
 
 
 
 DCs from early prediabetic female mice are charac-
terized by specific unresponsiveness to modulation of ac-
tivity by IFN-
 
 
 
 and by inability to counter the adjuvant
activity of IL-12 acting on CD8
 
 
 
 DCs.
 
Failure of IFN-
 
 
 
 to Induce Stat1-dependent Activation of
IDO in Early Prediabetic NOD Female Mice.
 
The tolero-
genic properties of CD8
 
 
 
 DCs are dependent on the activa-
tion of immunosuppressive tryptophan catabolism, which
may affect the proliferation and survival of NRP-A7-spe-
cific T cells (13, 17). To gain insight into the mechanism
underlying IFN-
 
 
 
 unresponsiveness in CD8
 
 
 
 DCs from
4-wk-old female mice, we measured IDO functional activity
in terms of ability to metabolize tryptophan to kynurenine
in vitro (Fig. 2 A). On comparing female and male mice of
4 or 8 wk of age, we found a selective inability of IFN-
 
 
 
 to
induce tryptophan catabolism in female mice at 4 wk. Both
NOD male mice and control C57BL/6 female mice were
susceptible to the enhancing effect of IFN-
 
 
 
 at 4 and 8 wk.
To investigate whether the defective IDO expression of fe-
male mice at 4 wk was due to inhibition of enzyme func-
tional activity or to impaired gene transcription, we ana-
lyzed IDO expression by Western blot using rabbit
polyclonal IDO-specific antibody (Fig. 2 B). Considerable
expression of the enzyme protein was induced by activation
Figure 1. CD8  DCs from early prediabetic NOD
female mice are not activated by IFN-  to suppress
NRP-A7 priming by CD8  DCs. Induction of skin
test reactivity to NRP-A7 was studied in 4-wk-old
hosts transferred with DC subtypes with or without cy-
tokine treatment. DCs from 8- or 4-wk-old mice were
fractionated according to CD8 expression and were
used as such (CD8 , CD8 ) or after treatment with
IL-12 (CD8 /IL-12) or IFN-  (CD8 /IFN- ). After
peptide pulsing, the different fractions were injected ei-
ther singly or in combination (indicated). Experimental
groups included the use of CD8  DCs treated with 2
 M 1-MT during exposure to IFN- . (*) P   0.001,
experimental versus control footpads. ND, not done.
One experiment is reported representative of five.
Figure 2. Failure of IFN-  to induce IDO expression and activity in
early prediabetic NOD female mice. (A) Functional IDO activity in re-
sponse to IFN-  was measured in vitro in terms of the ability to metabo-
lize tryptophan to kynurenine with the use of DCs recovered from NOD
female and male mice of two different ages (4 or 8 wk) or control
C57BL/6 female mice. Kynurenine levels in supernatants were measured
by HPLC, and results are the mean   SD of triplicate samples in one of
three experiments. (B) IDO expression in DCs was assessed by Western
blot. DCs were recovered from NOD female or male mice or control
DBA/2 females and treated overnight with IFN- , and IDO expression
was investigated with an IDO-specific antibody. The positive control
consisted of IDO-expressing MC24 transfectants and the negative control
consisted of mock-transfected MC22 cells. Loading controls (not shown in
the figure) consisted of samples reprobed with  -actin-specific antibody.
One experiments of three. (C) Stat1 phosphorylation in response to IFN- 
was studied in NOD female and male mice at 4 wk and in age-matched
control C57BL/6 female mice. DC lysates were resolved on SDS-PAGE
and immunoblotted with anti-phosphoStat1 and then reblotted with anti-
Stat1, reblots showing equal loading of Stat1 in each set of lanes. One of
three experiments with similar results.T
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with IFN-  in CD8  DCs from 4- or 8-wk-old NOD
male mice as well as DBA/2 controls. In NOD females,
IDO expression was induced by IFN-  at 8 but not 4 wk of
age. Thus, it appeared that IFN-  would not cause IDO ex-
pression in 4-wk-old female mice. This could be due to a
specific defect in the IFN-  signaling mechanism regulating
IDO expression in CD8  DCs. Because Stat1 phosphoryla-
tion is required for IFN- -induced transcription of the IDO
gene (10), we measured Stat1 phosphorylation in female
versus male mice at 4 wk (Fig. 2 C). In contrast to NOD
male mice and C57BL/6 controls, no Stat1 phosphorylation
was observed in NOD females in response to IFN- . Thus,
the failure of IFN-  to induce IDO expression in CD8 
DCs from early prediabetic female mice appeared to be as-
sociated with defective phosphorylation of Stat1.
Induction of Peroxynitrite by IFN-  and Antagonistic Effect of
GED on Peroxynitrite-induced Blockade of IFN-  Signaling.
In NOD mice, activated macrophages produce high
amounts of nitric oxide (NO), which is thought to contrib-
ute to the destructive phase of insulitis (19, 20). There is
evidence that tyrosine nitration of Stat1 by endogenous
NO may contribute to impaired response to IFN-  in acti-
vated macrophages. This effect is negated by inhibition of
NO synthase activity by concomitant treatment with
l-NMMA, a competitive inhibitor of the enzyme (21). To
investigate the possible involvement of NO in the defective
Stat1 phosphorylation observed in CD8  DCs from NOD
females in response to IFN- , we exposed these cells to the
cytokine in the presence of l-NMMA under conditions
known to restore macrophage responsiveness to IFN- 
(21). Using an experimental setting as described above, we
did not detect any effect of l-NMMA on Stat1 phosphory-
lation, IDO expression by Western blot analysis, or IDO
functional activity as induced by IFN-  (unpublished data).
Peroxynitrite is a highly reactive oxidant resulting from the
interaction of NO with superoxide, and is known to be
produced in acutely diabetic NOD mice (6). Peroxynitrite
may impair cell signaling via nitration of tyrosine residues
(22). An inhibitor of NO synthase and scavenger of per-
oxynitrite (i.e., GED) prevents diabetes development in
NOD mice (6). To investigate the possible production of
peroxynitrites by DCs from NOD mice, we assayed IFN-
 –induced production of nitrotyrosine in CD8  DCs from
4-wk-old female and male mice as well as control DBA/2
animals. NOD female mice were also assayed at 8 wk (Fig.
3). No nitrotyrosine formation was observed in cell super-
natants or lysates of DCs unexposed to IFN-  regardless of
donor type (data not depicted). In contrast, IFN-  induced
high levels of peroxynitrite selectively in DCs from NOD
female mice at 4 wk. In addition, GED prevented IFN- 
from inducing nitrotyrosine formation in these cells. In
parallel, we examined the effect of GED on IFN- –
induced Stat1 phosphorylation and IDO expression and
function (Fig. 4). GED restored Stat1 phosphorylation and
IDO protein expression (Fig. 4 A) as well as kynurenine
production (Fig. 4 B) in CD8  DCs from 4-wk-old NOD
female mice treated with IFN- . Because NO is a precur-
sor of peroxynitrite, the lack of activity of l-NMMA is not
easily explained but could be related to the different rela-
tive potencies of l-NMMA and GED in inhibiting enzyme
activity (21). Overall, these data demonstrate that CD8 
DCs from NOD female mice early in prediabetes produce
peroxynitrite in response to IFN- . This oxidant species
impairs the intracellular signal transduction pathways that
lead to Stat1 phosphorylation and IDO expression in re-
sponse to IFN- .
Ability of GED to Rescue IDO-dependent Tolerance Induc-
tion in CD8  DCs from Early Prediabetic NOD Female
Mice. Because of the ability of GED to restore IFN-  re-
sponsiveness in vitro in CD8  DCs from 4-wk-old NOD
Figure 3. Induction of peroxynitrite by IFN-  in CD8  DCs from early
prediabetic NOD female mice. CD8  DCs were recovered from NOD
female and male mice at 4 wk or from age-matched control DBA/2 female
mice to be incubated overnight with IFN- . NOD female mice were also
assayed at 8 wk. Nitrotyrosine in cell supernatants or lysates was assayed by
sandwich ELISA, the lower detection limit of the assay being 2 nM. Data
are means   SD of replicate samples in one of three experiments.
Figure 4. Ability of GED to restore IFN-  responsiveness in CD8 
DCs from early prediabetic NOD female mice. (A) GED was examined
for ability to restore IDO expression and Stat1 phosphorylation in re-
sponse to IFN- . CD8  DCs from 4-wk-old NOD female mice were
treated overnight with IFN-  and assayed for IDO expression or Stat1
phosphorylation. One experiment representative of three. (B) GED was
also studied for ability to restore kynurenine production by CD8  DCs
from the same donors. One experiment representative of three.T
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female mice, we wanted to investigate the effect of GED
on the in vivo ability of the latter cells to modulate priming
to NRP-A7 by CD8  DCs. We adopted an experimental
model analogous to that of Fig. 1, in which a combination
of CD8  and CD8  DCs was injected into NOD mice to
be assayed at 2 wk for skin test reactivity to the eliciting
peptide. DCs from 4-wk-old NOD female mice were frac-
tionated, treated with cytokines, loaded with the peptide,
and injected into recipient hosts. IL-12 was used to en-
hance the priming ability of CD8  DCs and IFN-  to in-
duce tolerizing properties in CD8  DCs, as illustrated
above. Groups of CD8  DCs were coexposed to 1-MT
and/or GED during IFN-  activation. As expected, IFN- 
treatment alone of CD8  DCs did not enable these cells to
prevent host priming to NRP-A7 (Fig. 5). However, the
copresence of GED during IFN-  activation rescued the
ability of CD8  DCs to suppress priming. The inhibitory
effect was dependent on tryptophan catabolism as it was
negated by the addition of 1-MT to IFN-  and GED.
These data demonstrate a role for peroxynitrite inhibition
of tryptophan catabolism in the poor tolerogenic ability of
DCs from NOD female mice in early prediabetes.
Discussion
Although IFN-  has been implicated in the induction of
tolerance in both autoimmunity (23) and transplantation
(24), there is no clear evidence to date that IDO-based im-
munoregulation may be operative in the control of au-
toimmunity. In contrast, there is evidence in pregnancy
(25) and transplantation (10) that, by locally depleting tryp-
tophan and increasing apoptotic kynurenines, IDO ex-
pressed by DCs greatly affects T cell proliferation (26) and
survival (27). IDO induction in DCs could be a common
mechanism of deletional tolerance driven by regulatory T
cells (12).
The NOD strain of mice has become a prototypic model
of autoimmune disease (1, 2). These mice generally die
from type 1 diabetes, reflecting the T cell–mediated de-
struction of pancreatic   cells, but also develop generalized
autoimmune disease affecting multiple organs. There is ev-
idence that disease susceptibility in NOD mice reflects a
defect in peripheral and central tolerance (3), although the
events linked to defective   cell tolerance within the T cell
compartment remain largely ill defined (28). These events,
however, are clearly influenced by multiple genetic and en-
vironmental factors (29). In this paper, we investigated
whether impaired tryptophan catabolism might be a factor
contributing to the breakdown of peripheral immunoregu-
lation and subsequent development of autoreactivity in
NOD mice.
Aberrant IL-12 production may predispose NOD mice
to autoimmunity (5). This could be reflected in our model
by the fact that the recombinant cytokine enhanced prim-
ing by CD8  DCs to NRP-A7, a peptide mimotope rec-
ognized by diabetogenic T cells in those mice (14, 15).
However, in conventional strains of mice, the effect of
IFN-  acting on tolerogenic CD8  DCs will prevail over
the adjuvant properties of IL-12 acting on CD8  DCs (13,
16, 17). Under conditions of host priming with peptide-
pulsed CD8  DCs whether or not activated by IL-12, not
only will the copresence of IFN- –activated CD8  DCs
inhibit priming by the other subset, but it will also initiate a
state of persistent unresponsiveness that has the characteris-
tics of deletional tolerance. This is demonstrated by the fact
that mice exposed to CD8  DCs treated with IFN-  will
fail to develop specific immunity at a later time when
treated with an otherwise immunogenic transfer of CD8 
DCs (17).
Functional dichotomy of CD8  and CD8  DCs, and
contrasting effects of IL-12 and IFN-  treatment, were
also found in this study on examining NRP-A7 presenta-
tion by CD8  and CD8  DCs from NOD male and
8-wk-old female mice (Fig. 1). Upon treatment with
IFN- –treated CD8  DCs, these mice developed a state
of long-term unresponsiveness that made them unrespon-
sive to subsequent, otherwise effective priming with
CD8  DCs (unpublished data). In contrast, IFN-  was
unable to induce suppressive or tolerizing properties in
DCs from NOD females in early prediabetes (Fig. 1). Two
considerations appear to be important in this regard. First,
the high incidence of diabetes observed in NOD female
mice might be related to the reduced tolerogenic ability of
DCs early in prediabetes. Second, the suppressive activity
of CD8  DCs from 8-wk-old female mice was contingent
upon effective tryptophan catabolism in these cells. Thus,
IDO activity might be critically involved in the induction
or maintenance of tolerance to autoantigens in NOD
mice, and IDO function might be defective in early predi-
abetic female mice.
Figure 5. Ability of GED to rescue the tolerizing prop-
erties of CD8  DCs from early prediabetic NOD female
mice. Combinations of CD8  and CD8  DCs were
loaded with NRP-A7 and injected into recipient mice to
be assayed at 2 wk for skin test reactivity to the eliciting
peptide. CD8  DCs were used as such or after activation
with IL-12, whereas CD8  DCs were exposed to IFN- .
Groups of CD8  DCs were coexposed in vitro to 1-MT
and/or GED before peptide loading. (*) P   0.001, experi-
mental versus control footpads. One experiment is reported
representative of three.T
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To explore this possibility, we examined IDO expres-
sion and function in female versus male mice of 4 or 8 wk
of age. Both IDO protein expression and function were se-
verely impaired in NOD females at 4 wk (Fig. 2, A and B).
Because transcriptional activation of the IDO gene is medi-
ated by Stat1 (10), we examined the possible occurrence of
defective Stat1 phosphorylation in response to IFN-  in
early prediabetic NOD female mice (Fig. 2 C). We ob-
tained clear evidence that Stat1 phosphorylation in re-
sponse to IFN-  was impaired in these mice. Aberrant
transcription factor activity is known to occur for nuclear
factor (NF)- B family members in NOD mice, with ele-
vated NF- B activation and aberrant production of IL-12
caused by intrinsic and unique patterns of NF- B expres-
sion in DCs (5, 30), as well as defective proteasome pro-
duction and NF- B activation in other cell types (31). Be-
cause NF- B is known to be activated by IFN-  (32),
these data suggested that in NOD mice, defective Stat1 sig-
naling might skew DCs toward enhanced activity mediated
transcriptionally by NF- B, such as production of IL-12
(33) and NO (34).
NOD mice are characterized by abnormal production of
NO, which might contribute to islet destruction by T cells
(20, 35). Tyrosine nitration of Stat1 by endogenous NO
may lead to impaired response to IFN-  in activated mac-
rophages (21). Peroxynitrite is a highly reactive oxidant
species produced by the combination of the free radicals,
superoxide and NO (36, 37). Peroxynitrite production has
been observed in acutely diabetic NOD mice (38), and
current evidence suggests that peroxynitrite is a more po-
tent and cytotoxic mediator than superoxide or NO alone
(37). An inhibitor of NO synthase and scavenger of per-
oxynitrite prevents diabetes in NOD mice (6). Tyrosine ni-
tration, a footprint of peroxynitrite, has been demonstrated
in the pancreatic islets as well as in the cardiovascular sys-
tem of diabetic subjects (39, 40).
We examined nitrotyrosine formation and the effect of
peroxynitrite inhibition in response to IFN-  in early pre-
diabetic NOD female mice (Fig. 3). On assaying CD8 
DCs from NOD female versus male or conventional mice,
we found high-level nitrotyrosine formation in both cell
supernatants and lysates of DCs from 4-wk-old NOD fe-
male mice. This effect was ablated by the copresence of a
peroxynitrite scavenger during cell exposure to IFN- .
Remarkably, the peroxynitrite scavenger also rescued Stat1
phosphorylation in response to IFN-  as well as kynure-
nine production in CD8  DCs from 4-wk-old NOD fe-
male mice (Fig. 4). These data strongly supported the con-
tention that tyrosine nitration of Stat1 by peroxynitrite
underlies the impaired response of the latter cells to IFN- ,
and may thus contribute to the failure to activate immuno-
suppressive tryptophan catabolism. Although the reason
why significant peroxynitrite formation is only seen in
NOD female mice in early prediabetes is unclear, it is pos-
sible that this production may be linked to the onset of in-
sulitis in a systemic inflammatory context in which the re-
dox status of APCs is abnormal (41). It is likely that the
reduced activity of superoxide dismutase observed in NOD
mice (42) results in increased peroxynitrite production and
protein tyrosine nitration.
Peroxynitrite scavenger-induced inhibition of nitroty-
rosine formation was also examined for possible effects on
the tolerogenic properties of CD8  DCs from NOD fe-
male mice upon treatment with IFN-  in vitro. A combi-
nation of peptide-pulsed CD8  and CD8  DCs from
4-wk-old female mice was injected into recipients to be as-
sayed for development of peptide-specific reactivity. CD8 
DCs were treated either with IFN-  alone or with IFN- 
in combination with 1-MT and/or the peroxynitrite scav-
enger. The results showed that treatment with GED fully
restored the induction of tolerance to NRP-A7 by CD8 
DCs, and this effect was dependent upon effective tryp-
tophan metabolism in these cells (Fig. 5). Rescue of the
suppressive activity of CD8  DCs by GED was associated
with the induction of persistent unresponsiveness to NRP-
A7, as induced by otherwise effective priming with CD8 
DCs performed up to 90 d after primary cell transfer (un-
published data). Thus, the effect mediated by the CD8 
DCs exposed to IFN-  and GED appears to be a true
switch from immunity to tolerance rather than a switch be-
tween different types of immunity (43).
By locally depleting tryptophan and increasing apoptotic
kynurenines, IDO expressed by DCs greatly affects T cell
proliferation and survival. IDO induction in DCs could be
a common mechanism of deletional tolerance driven by
regulatory T cells (12). Because such responses can be ex-
pected to operate in all forms of physiological tolerance,
tryptophan metabolism might be critically involved in the
prevention of autoimmune disorders. However, despite
much evidence for a role of IDO in mediating tolerance in
both pregnancy (25) and transplantation (10), there is no
evidence so far for a similar role of IDO in autoimmunity.
Our present data in NOD mice, a prototypic model of a
spontaneous autoimmune condition, provide evidence for
a link between impaired tryptophan catabolism and devel-
opment of autoreactivity. In NOD mice, several defects
contribute to the predisposition to develop autoimmunity.
Our data reveal a novel defect intrinsic to the DCs of
highly susceptible mice that may be involved in the failure
to initiate tolerance to self-antigens. Because DCs are cur-
rently regarded as the major discriminator of function in
the induction of tolerance versus immunity (44), and are
likewise considered to be a principal mediator of tolerance
(45), our current data emphasize the critical role of these
cells in maintaining an appropriate balance between toler-
ance and immunity. It is likely that the IDO-based path-
way is only one of several alternative modes of tolerance
(11). However, our current and previous data demonstrate
that a unitary mechanism involving DCs and IDO oper-
ates in the induction of tolerance in both transplantation
and autoimmunity.
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